Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.68 |
| ▸ | NPC1 | O15118 | 8/20 | 0.68 |
| ▸ | MEN1 | O00255 | 6/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.68 |
| ▸ | MAPT | P10636 | 7/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | STAT1 | P42224 | 1/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3869440 | 0.84 | MAPT (0.79) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL28906662 | 0.81 | RAB9A (1.00) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL3304391 | 0.76 | ALDH1A1 (0.56) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL3864415 | 0.73 | SMN1; SMN2 (0.55) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL1913687 | 0.72 | MAPT (1.00) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL10112053 | 0.72 | SMN1; SMN2 (0.59) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL28516248 | 0.72 | RAB9A (0.77) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL3869436 | 0.72 | KDM4E (0.43) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL1821288 | 0.72 | ALDH1A1 (0.83) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL27637107 | 0.71 | SMN1; SMN2 (0.52) | RAB9ASMN1; SMN2NPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112300157-B | Novel pyrazolopyridine compound with anti-tumor activity and preparation method thereof | 烟台大学 | 2021-08-20 | — | — | CN | disclosed |
| CN-112300157-A | Novel pyrazolopyridine compound with anti-tumor activity and preparation method thereof | 烟台大学 | 2021-02-02 | — | — | CN | disclosed |
| US-20090209451-A1 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-08-20 | — | — | US | disclosed |
| EP-1720863-A4 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORP (US) | 2009-04-22 | — | — | EP | disclosed |
| US-7517878-B2 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | BAYER PHARAMCEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
| EP-1720863-A2 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | Bayer Pharmaceuticals Corporation (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005086656-A2 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050192294-A1 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192294-A1 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | GPR119, GOT2, IAPP | RAB9A 2873/4885SMN1; SMN2 4413/4885NPC1 303/4885 |
| US-20090209451-A1 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | GPR119, GOT2, IAPP | RAB9A 2873/4885SMN1; SMN2 4413/4885NPC1 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.